> ## Content Index
> Fetch the complete content index at: https://www.theinvestorsociety.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Longevity Clinic Hone Health Lands US$228M
- URL: https://www.theinvestorsociety.com/longevity-clinic-hone-health-lands-us-228m-weeks-before-telehealth-rule-deadline/
- Published: 2026-11-19T16:00:00.000Z
- Updated: 2026-11-19T16:00:00.000Z
- Author: Katherine Castelán
- Tags: Western Hemisphere

Hone Health, a New York-based physician-led longevity platform, raised US$228M. The total comprises US$28M in Series A extension equity and US$200M in growth financing from General Catalyst’s Customer Value Fund (CVF). The equity round was led by MarcyPen Capital Partners, with participation from Pentland Ventures, Kinship Ventures, Hanwha, Gannet Capital and others, plus angel investors including David Grutman, Nick, Joe and Kevin Jonas, and Kelly Rowland. MarcyPen is the investment firm co-founded by Jay-Z. The round was announced on Wednesday, November 18, 2026, and brings Hone’s total equity funding to US$65M. 

Hone is led by co-founder and CEO Saad Alam. It was initially focused on testosterone and hormone optimization before expanding into weight management, cardiovascular health and menopause treatment. Its proprietary AI clinical platform, Longevity OS, combines biomarker testing, one-on-one physician consultations and personalized treatments. The company says it has treated more than 200,000 patients and administered 750,000 tests. Hone plans to use the funds to expand into metabolic, inflammation and immune health and to add diagnostics. It is also publicly launching Hone Black, a concierge longevity membership that has operated privately for the past year.

## Market Context

The structure of the deal matters more than the headline number. Only US$28M is equity, and it was raised as an extension of Hone’s Series A rather than as a Series B. The remaining US$200M comes from General Catalyst’s CVF, which works differently from a typical venture round. The fund receives a capped portion of the value generated by customers acquired with its money, and it is paid only when the company is paid. The model is meant to finance growth without additional equity dilution. According to Alam, the deal has no recourse and no covenants restricting Hone from raising other money. In effect, General Catalyst is betting on Hone’s customer economics: how much a member pays over time versus how much it costs to sign one up. 

The same fund has been active in consumer health. General Catalyst’s CVF backed Function Health with US$450M in growth financing, eight months after Function closed a US$298M Series B. Hone has traction behind its round as well. According to Alam, the company passed US$100M in recurring revenue last year. The new round follows a US$33M Series A announced in January 2025\. Hone competes in a crowded direct-to-consumer health market that includes testing-led platforms such as Function and prescription-led telehealth brands such as Hims & Hers. 

## What Stands Out

> “…what people are looking for is the highest level of insight into their metrics…”  
> — **Saad Alam, co-founder and CEO of Hone Health**, in the company’s announcement

![](https://storage.ghost.io/c/40/72/4072b0a5-dd13-4755-b3a4-f7b56403df30/content/images/2026/11/image-12.png)

## Regional Relevance

For the United States, Hone’s core business sits squarely in a regulatory gray zone that is about to be tested. Testosterone is a Schedule III controlled substance, so the federal deadline directly affects some at-home hormone-care workflows. The COVID-era flexibilities that let prescribers start and maintain controlled-substance prescriptions via telehealth without an in-person exam are set to expire on December 31, 2026\. A DEA final rule on a telemedicine special registration has reached White House review, and its form may significantly change how telehealth providers and platforms prescribe controlled substances. The size of this round, closing roughly six weeks before that deadline, is a signal that investors expect remote hormone care to survive in some regulated form. 

The deal also reflects a broader U.S. financing trend. Revenue-based capital such as the CVF lets consumer subscription businesses grow without repeated priced equity rounds. That model is spreading in health care, where companies with proven unit economics can borrow against future customer revenue instead of giving up ownership.

## The Other Side

**What happens if the DEA tightens telehealth prescribing on January 1?**  
If the flexibilities lapse without a replacement, the Ryan Haight Act would be fully reinstated, requiring an in-person exam before any telehealth controlled-substance prescription. That would add cost and friction to Hone’s original testosterone business. Hone’s diversification into menopause care, weight management and diagnostics reduces that exposure. 

**Is revenue-linked capital a strength or a constraint?** The CVF structure avoids dilution and, according to Alam, carries no covenants. However, the fund collects a capped share of value from the customers it finances. That works well only if members keep paying. If retention weakens, a larger share of revenue goes to the financier, and less is left to fund growth.

**Does the science support the product mix?** Longevity care spans well-established treatments and emerging ones such as peptides, where clinical evidence is thinner. Hone’s large dataset could become an advantage, but only if its clinical standards hold up to scrutiny as it scales into a concierge-style membership. 

## Sources & Transparency

- FinSMEs — [Hone Health Raises $228M in Funding](https://www.finsmes.com/2026/11/hone-health-raises-228m-in-funding.html?ref=theinvestorsociety.com)
- Fortune — [Hone Health lands $228 million with backing from Jay-Z’s firm and Gwyneth Paltrow. She’s an investor—and a patient](https://fortune.com/2026/11/18/hone-health-jay-z-gwyneth-paltrow-saad-alam-marcy-pen-ventures-raise/?ref=theinvestorsociety.com)
- Athletech News — [Hone Health Gets $228M to Expand Longevity Platform](https://athletechnews.com/hone-health-raises-228-million-longevity-care-marcypen-jay-z/?ref=theinvestorsociety.com)
- Tech Funding News — [Jay-Z’s MarcyPen and Gwyneth Paltrow’s Kinship back Hone Health’s $228M longevity round](https://techfundingnews.com/hone-health-raises-228m-marcypen-general-catalyst/?ref=theinvestorsociety.com)